Ronald R. Tuttle
29Patents
14h-index
34Co-inventors
81Inventor score
Filing activity: Jan 15, 1975 → Jul 13, 2000
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5460605A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | Emerging Cross-Sectional Technologies | 97 | Expired |
| US5286252A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | Emerging Cross-Sectional Technologies | 79 | Expired |
| US5108363A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | Emerging Cross-Sectional Technologies | 61 | Expired |
| US5658889A | Method and compounds for aica riboside delivery and for lowering blood glucose | Chemistry; Metallurgy | 53 | Expired |
| US5234404A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | Human Necessities | 49 | Expired |
| US6534503B1 | Melanocortin receptor-3 ligands to treat sexual dysfunction | Physics | 45 | Expired |
| US5420109A | Cytokine restraining agents | Chemistry; Metallurgy | 34 | Expired |
| US5760001A | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels | Human Necessities | 34 | Expired |
| US5726156A | Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels | Human Necessities | 33 | Expired |
| US5786332A | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels | Human Necessities | 30 | Expired |
| US6284735A | HP-3228 and related peptides to treat sexual dysfunction | Chemistry; Metallurgy | 25 | Expired |
| US5965536A | Methods of inhibiting CXC intercrine molecules | Human Necessities | 16 | Expired |
| US4774230A | Glucuronic acid derivatives of opioid antagonists | Chemistry; Metallurgy | 15 | Expired |
| US3987200A | Method for increasing cardiac contractility | Chemistry; Metallurgy | 14 | Expired |
| US4424209A | 3,4-Di -isobutyryloxy-N-3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phene thylamine cyclodextrin complexes | Chemistry; Metallurgy | 14 | Expired |
| US4425336A | 3,4-Dih ydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes | Chemistry; Metallurgy | 12 | Expired |
| US4946848A | Method of treating pruritus with nalmefene and clonidine | Human Necessities | 11 | Expired |
| US5888969A | Use of cytokine restraining agents to treat inflammatory bowel disease | Chemistry; Metallurgy | 10 | Expired |
| US4454142A | Hyperkinetic child treatment agent | Human Necessities | 9 | Expired |
| US6245738A | Cytokine restraining agents | Chemistry; Metallurgy | 9 | Expired |
| US4511570A | Senile dementia treatment | Human Necessities | 9 | Expired |
| US4562206A | Orally effective inotropic compounds | Chemistry; Metallurgy | 6 | Expired |
| US5643967A | Growth promotion | Chemistry; Metallurgy | 5 | Expired |
| US5741774A | Use of a cytokine regulatory agent to treat rheumatoid arthritis | Chemistry; Metallurgy | 3 | Expired |
| US5395970A | 1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol | Emerging Cross-Sectional Technologies | 2 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.